Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.

Nat Med · 2024 · PMC11485243 · PMID 38914124

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

However, there was a strong trend for SGLT2i to enhance albuminuria and heart failure benefits, but blunting benefits on myocardial infarction and stroke of the GLP-1 RA in AMPLITUDE-O 16 .

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.